Clinical trial · Expanded Access
A Single Patient Will be Treated With Individual Patient TCR-Transduced PBL
Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
NCT04194190CI-TRIAL-00046965no longer availableClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A single patient will be treated with Individual Patient TCR-Transduced PBL
Conditions
Conditions (0)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
Data not yet available
No condition recorded.
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Individual Patient TCR-Transduced PBL | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
Show eligibility criteria text
Inclusion Criteria: \- Exclusion Criteria: \-
References
Publications (0)
Data not yet available
No reference posted for this study.